Glimestar-M 1 Tablet PR contains a combination of Glimepiride 1 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This combination is indicated for patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy with either agent alone. Glimestar-M 1 Tablet PR is designed for prolonged release, allowing for sustained therapeutic effects and improved patient compliance through once-daily dosing. It is essential to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Hypoglycemia is a potential risk, primarily attributable to Glimepiride, necessitating patient education on recognizing and managing low blood sugar episodes. Glimestar-M 1 Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels.